CRISPR-CAS9 APPLICATIONS IN PERSONALIZED GENE THERAPY: ADVANCES AND ETHICAL CHALLENGES

Authors

  • Dr. Ambreen Zahra National Center for Genome Editing, Center for Advanced Studies/D-8 Research Center, University of Agriculture Faisalabad, Faisalabad, Pakistan. Author
  • Dr. Muhammad Irfan Fareed Assistant Professor, Biotechnology, UMT Sialkot, Sialkot, Pakistan. Author
  • Dr. Jennifer Doudna, Department of Chemistry, University of California, Berkeley, USA Author
  • Dr. Emmanuelle Charpentier Max Planck Unit for the Science of Pathogens, Berlin, Germany Author

DOI:

https://doi.org/10.71465/jhmri52

Keywords:

CRISPR-Cas9, personalized gene therapy, genome editing, ethical challenges, gene therapy, genetic disorders

Abstract

CRISPR-Cas9 technology has revolutionized personalized gene therapy by enabling precise genome editing. This paper explores the advancements in CRISPR-Cas9 applications for treating genetic disorders, focusing on its potential to tailor therapies to individual genetic profiles. However, the rapid development of this technology raises significant ethical concerns, including issues of consent, equity, and the potential for misuse. We examine these ethical challenges and discuss the need for regulatory frameworks to ensure responsible use of CRISPR-Cas9 in clinical settings.

 

References

Ahmad, N. R. (2026). AI-enabled public governance in developing states: Service delivery gains, accountability risks, and a practical risk-based regulatory model. Lex Localis - Journal of Local Self-Government, 24(S1), 99–117. https://doi.org/10.52152/wja5db40

image

Published

2023-03-31

Issue

Vol. 1 No. 1 (2023): Journal of Health, Medical Research and Innovations

Section

Articles

License

Copyright (c) 2023 Dr. Ambreen Zahra, Dr. Muhammad Irfan Fareed, Dr. Jennifer Doudna, , Dr. Emmanuelle Charpentier (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All articles published in the Journal of Health, Medical Research and Innovations are distributed under an open access license. Authors retain copyright and grant the journal the right of first publication. The published content can be freely accessed, shared, and reused for non-commercial purposes, provided proper citation is maintained and the original work is not altered.